Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Foundation Medicine Inc    FMI

FOUNDATION MEDICINE INC (FMI)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Foundation Medicine : Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Foundation Medicine, Inc. FMI

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/05/2017 | 07:35pm CEST

By a News Reporter-Staff News Editor at Managed Care Weekly Digest -- Glancy Prongay & Murray LLP ("GPM") reminds investors of the September 26, 2017 deadline in the class action lawsuit filed on behalf of investors who purchased Foundation Medicine, Inc. ("Foundation" or the "Company") (NASDAQ: FMI) securities between February 26, 2014 and November 3, 2015, inclusive (the "Class Period"). Foundation investors have until September 26, 2017 to file a lead plaintiff motion. To obtain information or participate in the class action, please visit the Foundation case page on our website at www.glancylaw.com/case/foundation-medicine-inc (see also Glancy Prongay and Murray LLP).

The Complaint filed in this class action alleges that, during the Class Period, the Company made false and misleading statements and/or failed to disclose adverse information regarding the Company's business and prospects. Specifically, the complaint alleges that the defendants made false and/or misleading statements regarding: (i) the reimbursement process and likelihood of coverage for Foundation's tumor tests by Medicare; and (ii) the Company's financial guidance. As a result of these false statements, Foundation common stock traded at artificially inflated prices during the Class Period.

On July 29, 2015, the Company disclosed that "clinical volume growth was affected by slower than anticipated progress towards obtaining a local coverage determination from our regional Medicare Administrative Contractor (MAC) and by some competitive noise in the market" and that, as such, the Company was "adjusting" its guidance for clinical volume and annual revenues. Then, on November 3, 2015, the Company disclosed a further revision to the already reduced number of clinical tests it expected to report for 2015.

On this news, the price of Foundation common stock fell $6.62 per share, to close at $17.31 per share on November 4, 2015.

Follow us for updates on Twitter: twitter.com/GPM_LLP.

If you purchased shares of Foundation during the Class Period you may move the Court no later than September 26, 2017 to ask the Court to appoint you as lead. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to [email protected], or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. View source version on businesswire.com: http://www.businesswire.com/news/home/20170925006403/en/

Keywords for this news article include: Medicare, Legal Issues, Health Policy, Glancy Prongay and Murray LLP.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC, source Health Newsletters

Stocks mentioned in the article
ChangeLast1st jan.
ROCHE HOLDING LTD. -0.66% 217.75 Delayed Quote.-11.08%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on FOUNDATION MEDICINE INC
04/20H3 Biomedicine Reports Discovery of Recurrent RNA Splicing Factor Mutations i..
AQ
04/13H3 Biomedicine to Present at 2018 American Association for Cancer Research An..
AQ
04/12REPORTS OUTLINE COLORECTAL RESEARCH : The Landscape of Amplification...
AQ
04/11FOUNDATION MEDICINE : and its Collaborators Present New Findings Supporting Tiss..
BU
04/09CANCER TREATMENT CENTERS OF AMERICA : and Foundation Medicine Launch Joint Educa..
PR
03/30FOUNDATION MEDICINE : Announces Commercial Availability of FoundationOne CDx&tra..
BU
03/22Foundation Medicine Advances Patient Access to Precision Medicine; Pursues Re..
AQ
03/21Chugai Starts Activities towards Commercialization of Foundation Medicine's P..
AQ
03/20FOUNDATION MEDICINE INC : Blog Exposure - Foundation Medicine Collaborated with ..
AC
03/20FOUNDATION MEDICINE : Announces Final National Coverage Determination (NCD) from..
AQ
More news
News from SeekingAlpha
04/23FOUNDATION MEDICINE : To Profit From The Increasing Trend Of Personalized Treatm.. 
04/22THE NO BS PLAN REPORT, WEEK 10 : Where The Reliable Falter 
04/15THE NO BS REPORT, WEEK 9 : Mostly Holding 
04/08THE NO BS REPORT, WEEK 8 : Welcome To The Downward Inflection? 
03/31THE NO BS REPORT, WEEK 7 : When Will These Stocks Rise Again? 
Financials ($)
Sales 2018 217 M
EBIT 2018 -156 M
Net income 2018 -158 M
Debt 2018 110 M
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 12,9x
EV / Sales 2019 8,99x
Capitalization 2 687 M
Chart FOUNDATION MEDICINE INC
Duration : Period :
Foundation Medicine Inc Technical Analysis Chart | FMI | US3504651007 | 4-Traders
Technical analysis trends FOUNDATION MEDICINE INC
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 79,5 $
Spread / Average Target 8,1%
EPS Revisions
Managers
NameTitle
Troy Cox President, Chief Executive Officer & Director
Michael J. Pellini Chairman
Konstantin Fiedler Chief Operating Officer
Jason Ryan CFO & Principal Accounting Officer
Vincent A. Miller Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
FOUNDATION MEDICINE INC7.84%2 687
CELLTRION, INC.--.--%28 789
IQVIA HOLDINGS INC-1.18%20 413
LONZA GROUP-7.22%18 571
INCYTE CORPORATION-28.05%14 432
NEKTAR THERAPEUTICS41.51%13 751